Published online before print September 6, 2005, doi: 10.1161/CIRCULATIONAHA.104.522110
(Circulation. 2005;112:1594-1600.)
© 2005 American Heart Association, Inc.
Imaging |
Chronic Thrombus Detection With In Vivo Magnetic Resonance Imaging and a Fibrin-Targeted Contrast Agent
From the Department of Cardiology (M.S.), Hôpital Lariboisière, Paris, France; the Zena and Michael A. Wiener Cardiovascular Institute and Marie-Josée and Henry R. Kravis Cardiovascular Health Center (M.S., V.F., J.J.B., J.T.F., P.R.M., Z.A.F.); the Imaging Science Laboratories (M.S., Z.A.F.), Department of Radiology; the Cardiovascular Biology Research Laboratory (J.J.B.); and the Department of Pathology (J.T.F.), Mount Sinai School of Medicine, New York, NY; and the Department of Physiology and Radioisotopes (J.-F.T.), Hôpital Européen Georges Pompidou, Paris, France.
Correspondence to Z.A. Fayad, PhD, Imaging Science Laboratories, Mount Sinai School of Medicine, Box 1030, One Gustave L. Levy Place, New York, NY 10029-6574. E-mail Zahi.Fayad{at}mssm.edu
Received November 19, 2004; revision received June 2, 2005; accepted June 9, 2005.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background— Arterial thrombosis plays a critical role in acute coronary syndromes and stroke. Therefore, the ability to detect thrombus in vivo has a significant clinical implication. Magnetic resonance imaging (MRI) has shown promise in noninvasive thrombus detection. However, thrombus characterization and age definition remain difficult. We sought to evaluate the use of a fibrin-targeted peptide (EP-2104R) for MR thrombus detection and to compare this modality with non–contrast-enhanced (NCE) MRI and with Gd-DTPA injection at various ages and time points after thrombus generation.
Methods and Results— Carotid artery thrombosis was induced by external injury and stasis in 18 rabbits. T1-weighted MRI was performed before and after contrast agent injection, within 6 hours of thrombus induction, at 48 hours, at 1 week, and every week up to 8 weeks after injury. Correlation with histopathology was performed. The fibrin-targeted contrast agent accurately detected all thrombi, regardless of their size, location, and age. Although thrombus signal intensity after injection decreased with thrombus age (P<0.001), enhancement at 8 weeks was still present. Gd-DTPA injection was not associated with an improvement of thrombus detection. EP-2104R was superior to both NCE and Gd-DTPA injection (P<0.001). Histopathologic examination showed thrombus organization over time. Fibrin was gradually replaced by fibrous tissue. A strong correlation was found between thrombus enhancement and collagen content of the organizing thrombus with time (R=–0.89; P<0.001).
Conclusions— In an experimental animal model of carotid thrombosis, we have demonstrated the superiority of a fibrin-targeted MR contrast agent for in vivo detection of chronic or organized thrombus, compared with NCE MRI and Gd-DTPA injection.
Key Words: atherosclerosis • contrast media • fibrin • magnetic resonance imaging • thrombosis
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Thrombus formation after erosion or rupture of atherosclerotic plaque is critical to the onset of acute coronary syndromes and stroke. Platelets and fibrin are the major components of all thrombi but may also be involved in the development and progression of atherosclerotic disease.1 Recent studies suggest that plaque rupture and microthrombus formation precede acute myocardial infarction by days to months,2 providing an opportunity to intervene and prevent the clinical manifestations associated with plaque rupture. Early detection of thrombus formation and age definition may be clinically helpful for both diagnosis and therapy. This may improve our ability to stratify the risk of potential clinical complications.
Although various imaging modalities, either invasive3 or noninvasive,4 have been used for detection of high-risk or vulnerable plaques, magnetic resonance imaging (MRI) has emerged as one of the most promising noninvasive imaging techniques for in vivo detection and characterization of atherosclerotic lesions.5–7 Non–contrast-enhanced (NCE) MRI has been reported to identify thrombi in vitro8 and in vivo in the aorta9 and in carotid arteries.10,11
Contrast agents such as conventional gadolinium (Gd) chelates have been shown to improve plaque characterization by enhancing the MR signal.12,13 Moreover, the recent development of novel, targeted MR contrast agents has led to molecular imaging of specific atherosclerotic plaque components.14 Paramagnetic and superparamagnetic MR contrast agents targeted to platelets, angiogenesis markers, or fibrin have been used successfully for thrombus imaging.15–20 Nevertheless, complete thrombus characterization with MRI remains difficult,21 and accurate age definition and chronic thrombus detection have not been possible so far.
We sought to evaluate the use of a fibrin-targeted peptide and compare it with NCE MRI and conventional Gd chelate injection (Gd-DTPA) for detection of occlusive and nonocclusive thrombi of different size, age, and time points after their generation in an experimental animal model of acute to chronic carotid artery thrombosis.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Animal Protocol
New Zealand White rabbits maintained on a normal diet (n=18; age 3 to 4 months; 3.5 to 4 kg body weight; Covance, Princeton, NJ) were used for this study. Arterial thrombosis was induced by carotid artery crush injury and blood stasis. The left common carotid artery was exposed after midline neck incision, under anesthesia (35 mg/kg IM ketamine and 7 mg/kg IM xylazine,). A deep external crush injury was performed on the carotid artery by using a circular hemostatic clamp capable of distributing a homogeneous circumferential pressure on the vessel wall (7-62 Lahey hemostatic forceps, curved; Miltex Instrument Co) as previously described.22,23 Injury was performed 1 cm below the carotid bifurcation with a variable length of 0.5 to 1.5 cm in a random manner. Approximately 3 minutes after repeated serial vessel damage, flow was reestablished. Then a stepwise stenosis was produced distally by constricting the artery with a 4-0 silk suture to reduce the flow by 40% (stenotic flow). Injury was always performed with the same hemostat and by the same operator (M.S.) to minimize variability. The Mount Sinai School of Medicine Institute Animal Care and Use Committee approved all experiments.
Contrast Agent
EP-2104R (Epix Pharmaceuticals) is a Gd-based contrast agent. EP-2104R is a small molecule that selectively and reversibly binds to fibrin. No interactions and competitive binding with other proteins such as fibrinogen or collagen have been noted in both in vitro and in vivo experiments (authors’ unpublished data). An earlier but very similar generation of the compound has been recently described in detail.20
Magnetic Resonance Imaging
Rabbits were sedated with ketamine/xylazine (as described earlier) and imaged in a supine position with a 1.5-T MRI system (Siemens). The injured artery and the contralateral normal carotid artery were imaged shortly after thrombus induction (
6 hours), at 48 hours, and at weeks 1, 2, 3, 4, 6, and 8 after thrombus induction (Figure 1).
|
After an initial rapid localization of the carotid arteries, a 3-dimensional (3D), time-of-flight MR angiogram was obtained from the aortic arch to the carotid bifurcation. Imaging parameters were as follows: repetition time/echo time/number of excitations=25/5/1 ms, and flip angle=20°. Five contiguous slabs, each containing 16 slices per slab, were imaged. Slice thickness was 0.8 mm. A field-of-view of 200 mm and matrix of 256x256 were used. The angiographic images were then reconstructed with a maximum-intensity projection (MIP) algorithm. Using the carotid bifurcation as an anatomic landmark, we obtained contiguous cross-sectional images perpendicular to the long axis of the neck with T1-weighted (T1W) and T2-weighted (T2W) double-inversion recovery, 22D turbo-spin echo sequences. The T1W and T2W images were acquired with a repetition time and echo time of 400/7 ms and 2300/62 ms, respectively. MRI parameters included a field of view of 8x8 cm; acquisition matrix of 256x256; 4 signal average; a receiver bandwidth of ±42 kHz; turbo factor of 16; and a slice thickness of 2 mm. No interslice gap was used. The inversion time after the double-inversion recovery pulses was 350 ms. In addition, a chemical shift–selective, fat-suppression pulse was used. A 2D phase-contrast MRI was then used to differentiate slow and absent flow from normal flow to confirm vessel patency. Two different expert observers examined the images to confirm absence of flow. Complementary imaging was performed, when necessary, to eliminate slow-flow artifacts by using a T1W 2D segmented gradient-echo sequence with a combination of inversion recovery and a diffusion-based, flow-suppression prepulse, as previously reported by our group.24
Images were acquired immediately before contrast agent administration (Figure 1) and 30 minutes after bolus injection (5 µmol/kg IV), based on preliminary data.23,25 The injection was immediately followed by a 10-mL saline flush (0.9% NaCl) in the same lateral ear vein.
Four additional New Zealand White rabbits were used to compare EP-2104R and a conventional Gd chelate (Gd-DTPA) for thrombus detection at different time points: acute (6 hours), subacute (1 week), 2-week-old, and 4-week-old thrombi. A protocol similar to that described previously was used. Gd-DTPA injection (50 µmol Gd/mL IV) was followed the next day by EP-2104R. A custom-made, 2-element (10x5.5 cm2) phased-array receive-only coil was used for signal reception.
Image and Data Analyses
An experienced observer, blinded to the experimental design (ie, to the time point after thrombus induction and to the side and size of carotid injury), performed the image data analysis. Images were analyzed with ImagePro Plus (Media Cybernetics). Because thrombus composition changes over time, we assessed the intrinsic MR properties of the thrombus by measuring the relative signal intensity (SI) to the reference muscle {SI (%)=100x[(SI thrombus)/(SI muscle)]} on T1W and T2W images (ie, in NCE images). The immediately adjacent muscle tissue equidistant from the surface phased-array coil was selected as a standard reference. For NCE MRI, the contrast-to-noise ratio (CNR) was determined 30 minutes after EP-2104R or Gd-DTPA injection [CNR=(SI thrombus–SI muscle)/SD noise] on MR images and was normalized to precontrast CNR. The SD of noise was determined within a region of interest drawn outside the animal. The individual values of SI measurements from 3 contiguous MR images were averaged for both precontrast and postcontrast images, and the mean SI at each time point was plotted over time. Thrombus SI was assessed in its lengthwise central portion, excluding the proximal and distal edges, because this central segment may better reflect thrombus age.10 Thrombus length was determined in MR images after EP-2104R injection by manual tracing in reconstructed MIP images.
Histopathology
To correlate the MRI findings with the histopathologic findings, 2 randomly selected animals were humanely killed immediately after MRI (100 mg/kg IV sodium pentobarbital) at each imaging time point. At the acute time point (6 hours) and the 1-week time point, 3 animals were killed. To avoid postmortem thrombus formation, euthanization was performed at the exact time of carotid excision. Because of artery length shrinkage after removal, carotid arteries were first stretched to the same length. The length of the carotid artery was then determined, and a linear correction factor was calculated, as previously described.9 Thereafter, carotid arteries were transferred to 4% paraformaldehyde solution for overnight fixation and then embedded in paraffin. Serial cross sections of selected carotid segments were taken (5-µm thickness) at 2-mm intervals to match the corresponding MR images. Specimens were then stained with the combined Masson’s elastin technique. The histopathologic sections of thrombotic carotid artery specimens were matched with corresponding MR images. Coregistration was performed carefully by using one or more anatomic landmarks, including the carotid bifurcation and the origin of the artery. An independent experienced pathologist, blinded to thrombus age and the MR findings, performed the histopathologic analysis and determined thrombus composition.
Statistical Analysis
Changes in SI and CNR over time were modeled in SAS with a mixed model approach with the PROC MIXED procedure for repeated measurements (SAS Institute Inc). Because both SI and CNR were measured during an 8-week period and analyzed with repeated measurements, the probability of correlation within animals is increased. The specific approach of repeated measurements used for this analysis allows for an accurate and improved estimate of the SEs of measurement and therefore, a more powerful test. To compare CNR before and after Gd-DTPA and EP-2104R before and after injection, differences among the 3 contrast techniques were explored and modeled with a 2-factor repeated-measures ANOVA, with repeated measures for both factors, ie, the change in contrast agent used and 4 replicate measurements per animal. A Pearson’s correlation coefficient was used to compare lengths of the thrombi obtained between MR images and histopathologic results. All measurements are expressed as mean±SE. P<0.05 was considered statistically significant.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Arterial thrombosis was successfully induced in all animals (n=18). Thrombi were totally obstructive in all cases but 4 (77.7%).
NCE MRI for Thrombus Detection
MR angiography with the 3D time-of-flight technique was not useful for occlusive thrombus detection because of flow signal dropout secondary to turbulent flow in the obstructed vascular segments. Thrombus transverse MR images on T1W and T2W turbo spin-echo sequences (ie, NCE MRI) showed time-dependent SI changes (Figure 2). In acute (ie, 6 hours) and subacute (ie, 1 week after induction) thrombi as well as in 2-week-old thrombi, relative SI was significantly higher in T2W than in T1W images. In chronic thrombi (ie, 
4 weeks after induction), relative SI was no longer different in T1W and T2W images.
|
Fibrin-Targeted Contrast Agent for Thrombus Detection
EP-2104R localized and accurately detected occlusive and nonocclusive thrombi, regardless of their location, size, and organizational stage (Figure 3). Relative SI and normalized CNR were significantly increased at each imaging time point (P<0.01) compared with precontrast T1W images. Over time, the CNR decreased significantly (P<0.001) with thrombus age (Figure 4). Acute and subacute thrombi were readily detected by EP-2104R. In chronic thrombus (ie, 4 weeks after induction), CNR was 2- to 4-fold higher (P<0.001) than on the T1W precontrast images. No difference was found between 6- and 8-week-old thrombi (P=0.3272), whereas CNR at 4 weeks after induction (4.28±1.21) was significantly higher (P<0.001) than at 6 weeks (3.12±1.06) after induction (Figure 4).
|
|
Because of the high MRI SI of EP-2104R–enhanced thrombi, targeted MIPs of carotid arteries could be reconstructed, and this readily allowed depiction of focal thrombi (Figure 5). Average thrombus length on MIP images was 9.2±4.5 mm (range, 4.9 to 13.7) and was correlated highly with histopathologic measurements (R=0.90, P<0.001). No difference in SI or CNR was noted between occlusive and nonocclusive thrombi. As expected, no changes were seen in the uninjured arteries (controls).
|
Gd-DTPA for Thrombus Detection
The use of Gd-DTPA was not associated with a significant improvement in thrombus detection, as confirmed by CNR values after Gd-DTPA injection in all animals (n=4) and at each time point. In 4-week-old thrombi (Figure 6), thrombus CNR was 1.18±0.72 at baseline and decreased to 1.08±0.87 after Gd-DTPA injection (P=NS). Gd-DTPA did not enhance the thrombus and provided only nonspecific enhancement of perivascular muscle. The same trend was observed at each imaging time point (ie, acute, subacute, or chronic thrombus). In contrast, thrombus CNR increased after EP-2104R injection to 4.62±0.97 (P=0.006) without any perivascular muscle enhancement (Figure 6).
|
Histopathologic Analysis of Thrombi
Thrombus composition reflected distinctive characteristics, as described in human studies. Histological study demonstrated chronological organization of the thrombi. Progressively, platelets and fibrin deposits were replaced by revascularized fibrocollagenous tissue, as shown in Figure 7. The acute thrombus showed histopathologic characteristics of heterogeneous, unorganized early thrombus, mostly red blood cells and fibrin-rich areas (Figure 7A). Platelet-rich conglomerates were densely packed and surrounded by layers of fibrin and red blood cells. Fibrin-rich areas were present mostly at the periphery of the artery, in particular, where the thrombus was attached to the areas of exposed media. A similar histological pattern was seen 48 hours after thrombus induction. At 1 week (Figure 7B), fibrin masses still appeared compacted, with the beginning of organization due to infiltration by macrophages, neointima, and fibroblast ingrowth from the periphery to the center of the thrombus. At 2 weeks, initial fibrotic replacement was detected inside the thrombus, with formation of layers of immature, collagenized, connective tissue, whereas unresorbed fibrin and cellular debris were still present. At 4 weeks, thrombus organization appeared more evident, with fibrous tissue occupying half of the area and the appearance of neovessels and smooth muscle cells. At 6 weeks (Figure 7C), the thrombus appeared completely organized, showing a dense collagen matrix, whereas the cellular content was reduced. At 8 weeks, fibrous tissue was no longer forming a dense matrix but was separated by numerous neovessels of various shapes and sizes, associated with adipocyte infiltration (Figure 7D). A strong, linear correlation (R=–0.89, P<0.001) was found between CNR as measured on MR images and thrombus collagen content (mm2) as measured by planimetry in histopathologic sections.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
In this study, we have demonstrated the superiority of contrast-enhanced MRI with a fibrin-targeted contrast agent for noninvasive thrombus detection in vivo. We report that EP-2104R plays a critical role in the discrimination not only between occlusive and nonocclusive arterial thrombi but also between thrombi of different sizes and ages (ie, recent and old thrombi). We have demonstrated the benefit of fibrin contrast-enhanced MRI for chronic thrombi detection compared with conventional Gd chelates and NCE MRI.
The MR appearance of arterial thrombi and the changes detected over time on NCE MRI (ie, T1W and T2W images) resulted from the combination of different oxygenation states of hemoglobin, changes in the intracellular and matrix content of proteins, and hydration of the cellular components, as already reported by our group.10 However, despite these temporal changes on T2W and T1W images, NCE MRI did not provide any information on the composition of the thrombus and did not allow reliable thrombus detection compared with EP-2104R, in particular, in chronic or organized thrombi.
Although these findings are considered preliminary and are limited by the relative small number of animals assessed by histopathology (2 to 3 per time point), they support the fact that EP-2104R improved detection of old and organized thrombi in vivo compared with NCE MRI and a conventional Gd chelate. Because fibrin is present in all types of thrombus (arterial and venous, acute and chronic) and in a low concentration in flowing blood, thus diminishing the background signal, fibrin is a favorable molecular imaging target. Therefore, EP-2104R enhances acute and chronic thrombi and permits imaging of large thrombi as well as submillimeter mural thrombi (Figure 3B). EP-2104R provided high signal enhancement of the entire thrombus, not just the thrombus surface, with good differentiation from thrombus-free segments of the vessel wall. EP-2104R yielded information on thrombus composition, highlighting the fibrin-rich areas, even in organized, old thrombi. Thrombus main composition (ie, presence of a large or small amount of fibrin within the thrombus) is important when considering the alternatives for efficient treatment of thrombotic phenomena.26
The mechanism by which EP-2104R seems to penetrate the thrombus is thought to be passive diffusion.27 However, according to the results of our study, although the mechanism of delivery might be passive diffusion, retention of the contrast agent is selective. EP-2104R, unlike Gd-DTPA, accumulates within the thrombus after binding to fibrin. Because of its high affinity for fibrin with tight binding and the apparent slow excretion kinetics relative to blood clearance of the compound, EP-2104R remains within the thrombus for 1.5 to 2 hours, as supported by preliminary work (M. Sirol et al, 2004, unpublished data).
Related Work
Although MRI has shown promise in thrombus detection in both experimental studies9,10 and humans,11 accurate thrombus age definition and detection of old and organized thrombi remain difficult. NCE MRI with the T1-shortening properties of methemoglobin (direct thrombus imaging)28 cannot be widely applied because of the relatively low content of red blood cells in arterial thrombi29 and uncertain thrombus time-course enhancement. NCE MRI with conventional Gd chelates has been reported to improve tissue characterization in human carotid arteries13 and enhance the contrast between the myocardium and intracardiac thrombi.30 However, Gd-DTPA is a nonspecific contrast agent that distributes to the intravascular and interstitial spaces by diffusion31 and does not allow for thrombus enhancement. Interestingly, no uptake of Gd-DTPA within the thrombus was noted at any imaging time in our study, in contrast to the perivascular muscle enhancement due to Gd-DTPA diffusion. Still, the exact identification and definition of thrombus age with Gd-DTPA remain difficult.21
Recent technical development has led to paramagnetic and superparamagnetic contrast agents that are targeted to thrombus components such as fibrin.8,15,18 Recently, the feasibility of in vivo acute thrombus detection with a fibrin-binding, MR contrast agent has been reported by our group23 and others.20 Nevertheless, no study had demonstrated the ability of chronic or organized thrombus detection in vivo with a targeted contrast agent with MRI.
Biological Assessment of Thrombus In Vivo With MRI
We have demonstrated that MRI SI decreases with thrombus age and is related to thrombus composition and organization. Thrombus enhancement due to the presence of fibrin deposits within it decreased in older thrombi in our experimental model of carotid thrombosis. The ability to image fibrin within thrombi in vivo may have significant clinical implications. Imaging fibrin may not only improve our knowledge of the kinetics and mechanism of thrombus formation but may also facilitate the design of safer and more effective therapeutic regimens based on fibrin inhibition and lysis. The administration of a fibrin-specific contrast agent may facilitate the understanding of thrombus behavior in vivo.
Clinical Relevance
Because thrombosis is a dynamic process, with thrombus material of different ages forming a layered structure due to successive mural deposition,32 fibrin-targeted, contrast-enhanced MRI may be used to differentiate between layers of fibrin deposits in all types of thrombi and in superimposed thrombosis associated with plaque rupture. Acute coronary syndromes, stroke, deep vein thrombosis complicated by pulmonary embolism, and atrial fibrillation with a high incidence of various cardiac manifestations result from thrombus formation in different vascular beds after either plaque rupture/erosion or increased blood thrombogenicity.33,34 Fibrin deposits in old, organized thrombi have recently been confirmed by histopathologic study after thrombectomy in percutaneous coronary intervention after acute myocardial infarction.35 Therefore, a noninvasive modality with a fibrin-targeted contrast agent might be ideal for in vivo detection of all thrombi. Potential applications include assessment of thrombus burden in patients with acute coronary syndromes and detection of coronary in-stent thrombosis.27 In addition, this technique may benefit patients with suspected deep venous thrombosis or pulmonary embolism36 and facilitate detection of atrial thrombus in patients with atrial fibrillation. Early-phase clinical studies (phases I and II) are currently testing the safety of EP-2104R in humans.
Conclusion
In this study, we demonstrate the benefit of contrast-enhanced MRI with a fibrin-targeted contrast agent for noninvasive chronic or organized thrombus detection in an experimental animal model of carotid artery thrombosis. We report the ability of EP-2104R to discriminate not only between occlusive and nonocclusive arterial thrombi in vivo but also between recent and old thrombi with respect to thrombus composition. We demonstrate the superiority of a fibrin-targeted MR contrast agent for thrombus detection compared with both Gd-DTPA and NCE MRI.
|
Acknowledgments |
|---|
This work was partially supported by the Fédération Française de Cardiologie, Paris, France (Dr Sirol); NIH/NHLBI HL071021 and HL078667 and Epix Pharmaceuticals Inc Cambridge, Mass (Dr Fayad); and the Mount Sinai Consortium for Cardiovascular Imaging Technology. The authors thank Dr Alan D. Weinberg, MS, from the Department of Surgery, Columbia University of College Physicians and Surgeons, New York, for statistical analysis, and Dan Samber, PE, from the Imaging Science Laboratories at Mount Sinai School of Medicine for editorial support.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Ruggeri ZM. Platelets in atherothrombosis. Nat Med. 2002; 8: 1227–1234.[CrossRef][Medline] [Order article via Infotrieve]
2. Ojio S, Takatsu H, Tanaka T, Ueno K, Yokoya K, Matsubara T, Suzuki T, Watanabe S, Morita N, Kawasaki M, Nagano T, Nishio I, Sakai K, Nishigaki K, Takemura G, Noda T, Minatoguchi S, Fujiwara H. Considerable time from the onset of plaque rupture and/or thrombi until the onset of acute myocardial infarction in humans: coronary angiographic findings within 1 week before the onset of infarction. Circulation. 2000; 102: 2063–2069.
3. MacNeill BD, Lowe HC, Takano M, Fuster V, Jang I-K. Intravascular modalities for detection of vulnerable plaque: current status. Arterioscler Thromb Vasc Biol. 2003; 23: 1333–1342.
4. Leber AW, Knez A, Becker A, Becker C, von Ziegler F, Nikolaou K, Rist C, Reiser M, White C, Steinbeck G, Boekstegers P. Accuracy of multidetector spiral computed tomography in identifying and differentiating the composition of coronary atherosclerotic plaques: a comparative study with intracoronary ultrasound. J Am Coll Cardiol. 2004; 43: 1241–1247.
5. Toussaint JF, LaMuraglia GM, Southern JF, Fuster V, Kantor HL. Magnetic resonance images of lipid, fibrous, calcified, hemorrhagic, and thrombotic components of human atherosclerosis in vivo. Circulation. 1996; 94: 932–938.
6. Fayad ZA, Fuster V, Fallon JT, Jayasundera T, Worthley SG, Helft G, Aguinaldo JG, Badimon JJ, Sharma SK. Noninvasive in vivo human coronary artery lumen and wall imaging using black-blood magnetic resonance imaging. Circulation. 2000; 102: 506–510.
7. Yuan C, Mitsumori LM, Ferguson MS, Polissar NL, Echelard D, Ortiz G, Small R, Davies JW, Kerwin WS, Hatsukami TS. In vivo accuracy of multispectral magnetic resonance imaging for identifying lipid-rich necrotic cores and intraplaque hemorrhage in advanced human carotid plaques. Circulation. 2001; 104: 2051–2056.
8. Johansson LO, Bjornerud A, Ahlstrom HK, Ladd DL, Fujii DK. A targeted contrast agent for magnetic resonance imaging of thrombus: implications of spatial resolution. J Magn Reson Imaging. 2001; 13: 615–618.[CrossRef][Medline] [Order article via Infotrieve]
9. Johnstone MT, Botnar RM, Perez AS, Stewart R, Quist WC, Hamilton JA, Manning WJ. In vivo magnetic resonance imaging of experimental thrombosis in a rabbit model. Arterioscler Thromb Vasc Biol. 2001; 21: 1556–1560.
10. Corti R, Osende JI, Fayad ZA, Fallon JT, Fuster V, Mizsei G, Dickstein E, Drayer B, Badimon JJ. In vivo non-invasive detection and age definition of arterial thrombus by MRI. J Am Coll Cardiol. 2002; 39: 1366–1373.
11. Moody AR, Murphy RE, Morgan PS, Martel AL, Delay GS, Allder S, MacSweeney ST, Tennant WG, Gladman J, Lowe J, Hunt BJ. Characterization of complicated carotid plaque with magnetic resonance direct thrombus imaging in patients with cerebral ischemia. Circulation. 2003; 107: 3047–3052.
12. Wasserman BA, Smith WI, Trout HH 3rd, Cannon RO 3rd, Balaban RS, Arai AE. Carotid artery atherosclerosis: in vivo morphologic characterization with gadolinium-enhanced double-oblique MR imaging initial results. Radiology. 2002; 223: 566–573.
13. Yuan C, Kerwin WS, Ferguson MS, Polissar N, Zhang S, Cai J, Hatsukami TS. Contrast-enhanced high resolution MRI for atherosclerotic carotid artery tissue characterization. J Magn Reson Imaging. 2002; 15: 62–67.[CrossRef][Medline] [Order article via Infotrieve]
14. Weissleder R, Mahmood U. Molecular imaging. Radiology. 2001; 219: 316–333.
15. Yu X, Song SK, Chen J, Scott MJ, Fuhrhop RJ, Hall CS, Gaffney PJ, Wickline SA, Lanza GM. High-resolution MRI characterization of human thrombus using a novel fibrin-targeted paramagnetic nanoparticle contrast agent. Magn Reson Med. 2000; 44: 867–872.[CrossRef][Medline] [Order article via Infotrieve]
16. Anderson SA, Rader RK, Westlin WF, Null C, Jackson D, Lanza GM, Wickline SA, Kotyk JJ. Magnetic resonance contrast enhancement of neovasculature with 
vß3-targeted nanoparticles. Magn Reson Med. 2000; 44: 433–439.[CrossRef][Medline]
[Order article via Infotrieve]
17. Schmitz SA, Winterhalter S, Schiffler S, Gust R, Wagner S, Kresse M, Coupland SE, Semmler W, Wolf KJ. USPIO-enhanced direct MR imaging of thrombus: preclinical evaluation in rabbits. Radiology. 2001; 221: 237–243.
18. Flacke S, Fischer S, Scott MJ, Fuhrhop RJ, Allen JS, McLean M, Winter P, Sicard GA, Gaffney PJ, Wickline SA, Lanza GM. Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques. Circulation. 2001; 104: 1280–1285.
19. Winter PM, Caruthers SD, Yu X, Song SK, Chen J, Miller B, Bulte JW, Robertson JD, Gaffney PJ, Wickline SA, Lanza GM. Improved molecular imaging contrast agent for detection of human thrombus. Magn Reson Med. 2003; 50: 411–416.[CrossRef][Medline] [Order article via Infotrieve]
20. Botnar RM, Perez AS, Witte S, Wiethoff AJ, Laredo J, Hamilton J, Quist W, Parsons EC Jr, Vaidya A, Kolodziej A, Barrett JA, Graham PB, Weisskoff RM, Manning WJ, Johnstone MT. In vivo molecular imaging of acute and subacute thrombosis using a fibrin-binding magnetic resonance imaging contrast agent. Circulation. 2004; 109: 2023–2029.
21. Kramer CM, Cerilli LA, Hagspiel K, DiMaria JM, Epstein FH, Kern JA. Magnetic resonance imaging identifies the fibrous cap in atherosclerotic abdominal aortic aneurysm. Circulation. 2004; 109: 1016–1021.
22. Zaman AG, Osende JI, Chesebro JH, Fuster V, Padurean A, Gallo R, Worthley SG, Helft G, Rodriguez OX, Fallon JT, Badimon JJ. In vivo dynamic real-time monitoring and quantification of platelet-thrombus formation: use of a local isotope detector. Arterioscler Thromb Vasc Biol. 2000; 20: 860–865.
23. Sirol M, Aguinaldo JGS, Graham PB, Weisskoff R, Lauffer R, Mizsei G, Chereshnev I, Fallon JT, Reis E, Fuster V. Fibrin-targeted contrast agent for improvement of in vivo acute thrombus detection with magnetic resonance imaging. Atherosclerosis. 2005; 182: 79–85.[Medline] [Order article via Infotrieve]
24. Sirol M, Itskovich VV, Mani V, Aguinaldo JGS, Fallon JT, Misselwitz B, Weinmann H-J, Fuster V, Toussaint J-F, Fayad ZA. Lipid-rich atherosclerotic plaques detected by gadofluorine-enhanced in vivo magnetic resonance imaging. Circulation. 2004; 109: 2890–2896.
25. Sirol M, Aguinaldo JGS, Itskovich VV, Aguiar SH, Chereshnev I, Wiethoff AJ, Parsons EC, Graham PB, Barrett JA, Weisskoff RM, Toussaint JF, Fayad ZA. Arterial thrombus detection and temporal evolution evaluation using in vivo molecular magnetic resonance imaging (MRI). Circulation. 2003; 108 (suppl IV): IV-98–IV-99.
26. Berenson GS, Srinivasan SR, Bao W, Newman WP 3rd, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults: the Bogalusa Heart Study [see comments]. N Engl J Med. 1998; 338: 1650–1656.
27. Botnar RM, Buecker A, Wiethoff AJ, Parsons EC Jr, Katoh M, Katsimaglis G, Weisskoff RM, Lauffer RB, Graham PB, Gunther RW, Manning WJ, Spuentrup E. In vivo magnetic resonance imaging of coronary thrombosis using a fibrin-binding molecular magnetic resonance contrast agent. Circulation. 2004; 110: 1463–1466.
28. Moody AR, Allder S, Lennox G, Gladman J, Fentem P. Direct magnetic resonance imaging of carotid artery thrombus in acute stroke. Lancet. 1999; 353: 122–123.[CrossRef][Medline] [Order article via Infotrieve]
29. Cotran RS, Kumar V, Collins T, Robbins SL. Robbins Pathologic Basis of Disease. Philadelphia: WB Saunders Co; 1999.
30. Mollet NR, Dymarkowski S, Volders W, Wathiong J, Herbots L, Rademakers FE, Bogaert J. Visualization of ventricular thrombi with contrast-enhanced magnetic resonance imaging in patients with ischemic heart disease. Circulation. 2002; 106: 2873–2876.
31. Merbach AA, Toth E, eds. The Chemistry of Contrast Agents in Medical Magnetic Resonance Imaging. Chischester, England: John Wiley & Sons; 2001.
32. Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death: autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation. 1985; 71: 699–708.
33. Fuster V. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation. 1994; 90: 2126–2146.
34. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995; 92: 657–671.
35. Rittersma SZH, van der Wal AC, Koch KT, Piek JJ, Henriques JPS, Mulder KJ, Ploegmakers JPHM, Meesterman M, de Winter RJ. Plaque instability frequently occurs days or weeks before occlusive coronary thrombosis: a pathological thrombectomy study in primary percutaneous coronary intervention. Circulation. 2005; 111: 1160–1165.
36. Spuentrup E, Buecker A, Katoh M, Wiethoff AJ, Parsons EC Jr, Botnar RM, Weisskoff RM, Graham PB, Manning WJ, Gunther RW. Molecular magnetic resonance imaging of coronary thrombosis and pulmonary emboli with a novel fibrin-targeted contrast agent. Circulation. 2005; 111: 1377–1382.
 |
|
 |
|
  R.-J. J.H.M. Miserus, M. V. Herias, L. Prinzen, M. B.I. Lobbes, R.-J. Van Suylen, A. Dirksen, T. M. Hackeng, J. W.M. Heemskerk, J. M.A. van Engelshoven, M. J.A.P. Daemen, et al. Molecular MRI of Early Thrombus Formation Using a Bimodal {alpha}2-Antiplasmin-Based Contrast Agent J. Am. Coll. Cardiol. Img., August 1, 2009; 2(8): 987 - 996. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Nahrendorf, D. E. Sosnovik, B. A. French, F. K. Swirski, F. Bengel, M. M. Sadeghi, J. R. Lindner, J. C. Wu, D. L. Kraitchman, Z. A. Fayad, et al. Multimodality Cardiovascular Molecular Imaging, Part II Circ Cardiovasc Imaging, January 1, 2009; 2(1): 56 - 70. [Full Text] [PDF]
|
|
|
|
 |
|
 W P Bandettini and A E Arai Advances in clinical applications of cardiovascular magnetic resonance imaging Heart, November 1, 2008; 94(11): 1485 - 1495. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Lancelot, V. Amirbekian, I. Brigger, J.-S. Raynaud, S. Ballet, C. David, O. Rousseaux, S. Le Greneur, M. Port, H. R. Lijnen, et al. Evaluation of Matrix Metalloproteinases in Atherosclerosis Using a Novel Noninvasive Imaging Approach Arterioscler Thromb Vasc Biol, March 1, 2008; 28(3): 425 - 432. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. A. Jaffer, P. Libby, and R. Weissleder Molecular Imaging of Cardiovascular Disease Circulation, August 28, 2007; 116(9): 1052 - 1061. [Full Text] [PDF]
|
|
|
|
 |
|
 X. Yang Nano- and Microparticle-based Imaging of Cardiovascular Interventions: Overview Radiology, May 1, 2007; 243(2): 340 - 347. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Wiart, N. Davoust, V. Desestret, N. Nighoghossian, and Y. Berthezene Response to Letter by Bendszus et al Stroke, May 1, 2007; 38(5): e13 - e13. [Full Text] [PDF]
|
|
|
|
|
|
C. P. Stracke, M. Katoh, A. J. Wiethoff, E. C. Parsons, P. Spangenberg, and E. Spuntrup Molecular MRI of Cerebral Venous Sinus Thrombosis Using a New Fibrin-Specific MR Contrast Agent Stroke, May 1, 2007; 38(5): 1476 - 1481. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Sosnovik, M. Nahrendorf, and R. Weissleder Molecular Magnetic Resonance Imaging in Cardiovascular Medicine Circulation, April 17, 2007; 115(15): 2076 - 2086. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||